Cancer Vaccines

Subscribe to Selected New Research on Cancer Vaccines

809 relevant articles (93 outcomes, 114 trials/studies) found for this Bio-Agent

Description: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.

Also Known As:

Neoplasm Vaccines; Tumor Vaccines; Vaccines, Cancer; Vaccines, Neoplasm; Vaccines, Tumor

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ostrand-Rosenberg, Suzanne: 3 articles (03/2008 - 04/2004)
2.	Ksander, Bruce R: 2 articles (03/2008 - 01/2006)
3.	Greiner, Jochen: 2 articles (12/2006 - 12/2005)
4.	Schmitt, Michael: 2 articles (12/2006 - 12/2005)
5.	Levitsky, Hyam I: 2 articles (01/2006 - 02/2003)
6.	Mullen, Craig A: 2 articles (04/2005 - 03/2002)
7.	Disis, M L: 2 articles (05/2000 - 01/2000)
8.	Vonderheide, Robert H: 1 article (09/2008)
9.	Beatty, Gregory L: 1 article (09/2008)
10.	Smyth, Mark J: 1 article (04/2008)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2009 - "The high efficacy of the two available cervical cancer vaccines and their proven ability to reduce the incidence of cervical cancer precursor lesions offer hope that the vaccine will have enormous worldwide impact and may dramatically reduce the cervical cancer burden. " 06/15/2008 - "Most of the current tumor vaccines successfully elicit strong protection against tumor but offer little therapeutic effect against existing tumors, highlighting the need for a more effective vaccine strategy. " 04/01/2006 - "However, experimental cancer vaccines, although in some patients result in elimination of large tumor burdens, have a low frequency of long-term cancer remission in most patients, ca. <5%. " 10/01/2003 - "As prophylactic tumor vaccines, the combined use of gene-modified BM1/sFlt3L+GM-CSF+IL-12 x CD80 was most effective, providing 100% protection against subsequent parental BM1 tumor challenge. " 01/01/2005 - "Important considerations that are discussed include the method of selection of potential cancer vaccine cells that would make good models for cancer vaccines for human cancers, the effects of in vitro IFN-alpha treatment concentration on the efficacy of generated cancer vaccine cells, the differential ability of cancer cells to become efficacious cancer vaccine cells in response to IFN-alpha treatment, the determination of the effectiveness of ultraviolet-light killing of various cancer cell types for generating cancer vaccine cells, and the methods of evaluation of statistical significance of the data obtained. " Order ALL the reference details at left...
2.	Melanoma (Melanoma, Malignant) 08/01/2003 - "To test whether homeostasis-driven T cell proliferation in reconstituted lymphodepleted hosts would improve the therapeutic efficacy of tumor vaccines, normal mice and reconstituted lymphopenic mice (RLM; C57BL/6 mice rendered lymphopenic with sublethal total-body irradiation and reconstituted with naive splenocytes) were used in the vaccination and challenge experiments with weakly immunogenic F10 melanoma cells. " 04/01/2003 - "At present, there are no FDA-approved cancer vaccines for malignant melanoma, and the results of ongoing randomized phase III clinical trials are greatly anticipated." 09/01/2009 - "Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model." 10/01/2008 - "These data suggest that GILT-expressing melanoma cells could prove to be very promising for direct antigen presentation and CD4+ T cell recognition, and may have direct implications for the design of cancer vaccines." 02/01/2007 - "Despite this understanding and its application to melanoma patients in the form of various tumor vaccines, advanced-stage melanoma continues to be a devastating disease, associated with significant morbidity and mortality. " Order ALL the reference details at left...
3.	Residual Neoplasm 06/01/2003 - "Promising therapeutic clinical activity has been demonstrated, and other studies have shown that cancer vaccines are most beneficial for minimal residual disease states. " 03/01/2008 - "Preclinical and clinical research had indicated that cancer vaccines exert optimal benefit in earlier stage disease or in adjuvant/minimal residual disease (MRD) settings. " 09/01/2007 - "A promising area of investigation is the use of cancer vaccines to eliminate residual tumor cells. " 12/01/2005 - "For all cancer vaccines there is mounting evidence that the stage of disease to be targeted is minimal residual disease or in adjuvant settings." 01/01/1999 - "CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease." Order ALL the reference details at left...
4.	Breast Neoplasms (Breast Cancer) 02/01/2004 - "In this study, we used syngeneic metastatic (4TO7) and non-metastatic (64pT) breast tumor models to obtain valuable information on the potential usefulness of MAGE-encoding cancer vaccines in metastatic and non-metastatic breast cancer at old age. " 05/01/2009 - "Tumor vaccines for breast cancer." 12/01/2007 - "Immunology and breast cancer: therapeutic cancer vaccines." 05/01/2005 - "Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. " 09/01/2003 - "Cancer vaccines have several therapeutic advantages over more traditional breast cancer treatment modalities. " Order ALL the reference details at left...
5.	Carcinoma (Carcinomatosis) 01/01/2004 - "The obtained data indicate that the IL-12-transduced murine colon carcinoma cells could be used both as a model tumour for the study of mechanisms of anticancer immunity and/or as an adjuvant to cancer vaccines." 08/01/2002 - "Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines." 02/01/2008 - "HLA class I loss is a significant mechanism of immune evasion by cervical carcinoma, interfering with the development of immunotherapies and cancer vaccines. " 07/01/1997 - "Active-specific immunotherapy of pancreatic carcinoma: usefulness of human pancreatic carcinomas in preparing autologous tumor vaccines." 09/01/2006 - "CONCLUSION: Our data indicate that suicidal cancer vaccine is an effective and safe therapy for ovarian carcinoma and may serve as a broadly applicable approach for other cancer vaccines in the future." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antigens
2.	Vaccines
3.	Cytokines
4.	Interleukin-2 (IL2)
5.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
6.	Epitopes
7.	Peptides
8.	DNA (Deoxyribonucleic Acid)
9.	Interleukin-6 (Interleukin 6)
10.	Interleukin-12 (IL 12)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Biological Therapy
4.	Chemoprevention
5.	Laparotomy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>